191 results about "Viral type" patented technology

The invention provides a three-color fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) combined detection method of enterovirus 71, Coxsackie virus A16 and other subtypes of enterovirus as well as a kit thereof. The method can rapidly and accurately detect the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of enterovirus in a sample. The method comprises the following steps of: (1) acquiring and conveying a sample of an infected patient or a suspected patient; (2) preprocessing the sample and extracting RNA; (3) detecting the sample by adopting a one-step PCR-three-color fluorescent probe in-vitro amplification method; and (4) analyzing the corresponding sample according to the fluorescence intensity of each amplification reaction after the amplification reaction is finished, thereby judging the existence of the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus in the acquired sample and being capable of carrying out accurate quantitation (a figure 3) on the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus. The invention realizes the aim of carrying out rapid and accurate combined detection of the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus.

The invention relates to preparation of a vaccine for hand-foot-and-mouth disease viruses and an application method thereof, belonging to a novel vaccine for preventing infectious diseases. The vaccine of the invention mainly comprises the components of high-purified inactivated human enteropathogenic virus 71 (EV 71) and an aluminum adjuvant. The vaccine, which is prepared according to the method of the invention, has excellent immunogenicity, and after immunity, organisms can selectively generate a high titer serum neutralization antibody, thereby preventing infectious diseases caused by the human EV 71.

The invention relates to an application of tetrahydroindolone/ tetrahydroindazolone/ tetrahydrocarbazole derivatives and salts thereof in the preparation of antiviral drugs. The tetrahydroindolone derivatives, the tetrahydroindazolone derivatives or the tetrahydrocarbazole derivatives, as well as the salts thereof of the invention have anti-viral functions, and the virus comprises I-typed and II-typed herpes virus, coxsackie virus type 3 (CVB3) and hepatitis B virus.

The invention discloses a preparation method for a recombinant coxsackie virus A16 like particle, which comprises the following steps: (1) cloning a P1 gene and a 3CD gene of a coxsackie virus A16 to a target plasmid to obtain a recombinant expression vector; (2) transforming a target yeast cell by using the recombinant expression vector obtained in the step (1) to obtain a recombinant yeast cellfor expressing the P1 gene and the 3CD gene; and (3) cracking the recombinant yeast cell obtained in the step (2), and separating to obtain the recombinant coxsackie virus A16 like particle. The recombinant coxsackie virus A16 like particle can be prepared in a yeast expression system by the method provided by the invention. Compared with a wild-type P1 gene and a wild-type 3CD gene, the yield ofthe coxsackie virus A16 like particle in the yeast expression system is greatly increased through the optimization of codons of the P1 gene and the 3CD gene, and the recombinant coxsackie virus A16 like particle can be further used for producing candidate preventive vaccines and pharmaceutical compositions for infant hand-foot-and-mouth diseases.

The present invention relates to human papillomavirus (HPV) type hybrid virus-like particles and a preparation method thereof. The virus-like particles can be used for preventions two or more HPV infections and diseases caused by HPV infections. The present invention further relates to uses of the protein and the virus-like particles in preparations of drug compositions or vaccines, wherein the drug compositions or the vaccines are provided for preventions of HPV infections and diseases caused by HPV infections, and the diseases comprise cervical cancer, condyloma acuminatum, and the like.

The invention provides a Coxsackie virus A16 virus strain, uses of the strain, a vaccine and a preparation method of the vaccine. The preservation number of the Coxsackie virus A16 virus strain is CGMCC No.6954. The CA16 virus strain has strong virulence, can be used for evaluating the CA16 vaccine, and can also be used for researching the CA16 virus infection mechanism. A method for establishing a Coxsackie virus A16 infected animal model provided by the invention can provide a stable animal model, and provides a foundation for the development of the Coxsackie virus A16 vaccine, the screening of antiviral drugs and the researches of the CA16 virus infection mechanism. The vaccine prepared by using the CA16 virus has effective immune activity.

The present invention discloses recombinant pig influenza virus NP antigen and its preparation process and application in diagnosis. Type-A influenza virus genome consists of 8 segments of RNA, and its nucleoprotein (NP) has type and group specificity and is the basis of typing diagnosis. The recombinant pig influenza virus NP antigen has colibacillus prokaryotic expression system to express complete NP gene of separated pig influenza virus strain in China, and the expressed NP is used as antigen in detecting type-A influenza virus infection produced anti-NP protein antibody. The NP gene is the basis for classifying and diagnosing pig influenza virus with many subtypes. Therefore, the diagnosis technology established based on recombinant SIV NP antigen may be used in detecting type-A influenza virus infection of pig, fowl, horse and human.

The invention relates to the field of biomedicine, and specifically relates to an enterovirus 71 antigen detection test strip (colloidal gold method) and a preparation method and application thereof. Enterovirus 71 can cause hand-foot-and-mouth disease, which has largegeneration proportion of severe infections (viral encephalitis, meningomyelitis virus and pulmonary edema), and a high death rate reaching 10%-25%. The test strip of the invention is used for rapid diagnosis of EV(enterovirus)71 infection. A virus separation and an RT-PCR (reverse transcription-polymerase chain reaction) are methods first used for EV71 antigen detection, but are not suitable for primary clinic usage due to defects of difficult operation and high costs, etc. The invention overcomes the above insufficiencies and provides a reagent, which is highly demanded in clinic detection, simply operated, suitable for various medical disease control sections, and capable of detecting EV71 antigens in human oropharyngeal swabs, bubble liquid, serum or excrement, and also provides the preparation method and application thereof. A technical scheme is as follows: a specimen is dropped on a sample pad, and the EV71 antigen wherein combines with a gold-labeled EV71 polyclonal antibody in a gold-labeled pad and migrates along a chromatography membrane. A detected line captures colloidal gold particles to form a red line visible to naked eyes, so as to realize detection of the EV71 antigen.

The invention relates to an enterovirus 71 type latex agglutination detection kit, preparation and application. The kit comprises the following substances: (1) a carboxylated latex reagent sensitizing a prokaryotic expression enterovirus 71 type VP1 specific antigen; (2) a carboxylated latex reagent sensitizing three strains of monoclonal mixed antibodies aiming at enterovirus 71 type VP1; (3) enterovirus 71 type positive-negative standard serum, an inactivated virus solution and PBS; and (4) a toothpick or a plastic cement rod which contains a glass slide platform for using the sentization latex to perform aggregation reaction and is used to uniformly mix latex and to-be reacted serum. The kit can detect EV71 antigen in samples of different sources, and overcomes the disadvantages that the sensitized antigen is less in amount and unstable, sensitized protein is easy to fall off, and the like when protein sensitizes common latex. The detection method is applicable to enterovirus 71 type serum epidemiological investigation, clinic assistant diagnosis, regulation and control on EV71 virus replication, anti-virus therapy medicine screening and other scientific research fields.

The invention discloses a recombinant protein coded by GCRV (grass carp reovirus) II type S9 genes and application thereof. The amino acid sequence of the recombinant protein is shown as SEQ ID NO:2. The nucleotide sequence for coding the protein is shown as SEQ ID NO:1. The obtained recombinant protein has better immunogenicity. Compared with CGRV proteins of other structures, the recombinant protein has the advantage that the valence of specific antibodies generated by immune animals induced by the protein is higher. Further experiments show that when VP6 proteins are used for immunizing grass carps, the grass carps can be induced to generate higher specific antibody; a certain immune protection effect is achieved on the GCRV strong virus plant attack. Therefore the development and the application of the GCRV II type VP6 protein have very important significance on developing novel grass carp hemorragic disease vaccine and immunological detection kits, and a novel effective solution path is provided for grass carp hemorragic diseases.

The invention relates to an ELISA (enzyme-linked immunosorbent assay) kit for an EV (enterovirus) 71 inactivated vaccine antigen. The detection kit comprises an EV71 pre-coated polyclonal antibody ELISA plate, a sample diluent, a second antibody, an enzyme-labeled antibody, a concentrated cleaning solution, an enzyme substrate solution and a stop buffer, wherein the ELISA plate is pre-coated with a polyclonal antibody prepared by taking recombinant EV71 structural protein 1 as an immune source; the second antibody adopts a monoclonal antibody prepared by taking keyhole limpet hemocyanin coupled polypeptide sequence FGEHKQEKDL as the immune source; the enzyme-labeled antibody adopts a horse radish peroxidase labelled goat anti-mouse immunoglobulin antibody; and an antibody standard is placed in the kit. The ELISA kit has better sensitivity when measuring the titer of the EV71 inactivated vaccine antigen, and has better linearity in the range of 5.9-750 ng/ml, and the linearly dependent coefficient r2 is larger than 0.99. The kit for measuring the titer of the EV71 inactivated vaccine antigen simply and conveniently has good specificity, accurate quantification, high sensitivity and good repeatability.